HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...